<DOC>
	<DOCNO>NCT00838240</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine , cytarabine , idarubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This randomized phase I/II trial study side effect best dose clofarabine see well work give together cytarabine idarubicin treat patient intermediate-risk high-risk acute myeloid leukemia high-risk myelodysplasia .</brief_summary>
	<brief_title>Clofarabine , Cytarabine , Idarubicin Treating Patients With Intermediate-Risk High-Risk Acute Myeloid Leukemia High-Risk Myelodysplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine optimum dose clofarabine combination cytarabine idarubicin patient previously untreated intermediate- high-risk acute myeloid leukemia high-risk myelodysplasia . ( Phase I ) - To determine safety tolerance regimen order determine recommend phase II dose . ( Phase I ) - To explore antitumor activity regimen patient . ( Phase II ) - To determine activity express complete remission ( CR ) /CR incomplete hematopoietic recovery ( CRi ) rate follow induction therapy . ( Phase II ) Secondary - To determine activity express CR/CRi rate follow induction ( 1 2 course ) consolidation therapy . ( Phase I ) - To determine hematopoietic recovery ( platelet neutrophils ) induction consolidation therapy . - To determine safety tolerability regimen . ( Phase II ) - To determine activity express CR/CRi rate consolidation therapy . ( Phase II ) - To determine feasibility blood CD34 harvest consolidation therapy . ( Phase II ) - To determine disease-free overall survival CR/CRi . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study clofarabine follow randomized phase II study . Patients stratify accord center , presence poor prognostic feature ( WBC diagnosis ≥ 100,000/μL v presence high risk cytogenetic feature -5/5q- , -7/7q- , presence complex abnormality [ &gt; 3 abnormality ] , 3q , [ 6 ; 9 ] , [ 9 ; 22 ] ) . Patients randomize 1 2 treatment arm . - Induction therapy : - Arm I : Patients receive idarubicin IV 5 minute day 1 , 3 , 5 , cytarabine IV continuously day 1-10 , clofarabine IV 1 hour day 2 , 4 , 6 , 8 , 10 . - Arm II : Patients receive idarubicin IV cytarabine IV arm I . Patients also receive clofarabine IV push injection 10 minute day 2 , 4 , 6 , 8 , 10 . - Consolidation therapy : Patients receive cytarabine IV 2 hour every 12 hour day 1-6 idarubicin IV 5 minute daily day 4-6 . After completion study therapy , patient follow periodically 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow WHO criterion : Acute myeloid leukemia ( AML ) ( ≥ 20 % bone marrow blast bone marrow aspiration biopsy ) No acute promyelocytic leukemia ( M3 ) All cytogenetic group allow , except follow : ( 15 ; 17 ) ( 8 ; 21 ) inv ( 16 ) AND WBC count diagnosis &lt; 100,000/μL Primary secondary AML allow , include AML myelodysplasia ( MDS ) Highrisk MDS ( ≥ 10 % bone marrow blast bone marrow aspiration biopsy ) No chronic myelogenous leukemia blast crisis AML supervene myeloproliferative disorder Previously untreated disease , except ≤ 14 day hydroxyurea No CNS leukemia PATIENT CHARACTERISTICS : WHO performance status 02 Serum creatinine ≤ 1.0 mg/dL glomerular filtration rate &gt; 60 mL/min AST/ALT ≤ 2.5 time upper limit normal ( ULN ) ALP ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception ≥ 3 month completion study treatment No active uncontrolled infection No HIV positivity No psychological , familial , sociological , geographical condition preclude compliance study treatment follow No concurrent severe uncontrolled cardiovascular disease ( i.e. , symptomatic congestive heart failure symptomatic ischemic heart disease [ NYHA class IIIIV ] ) No concurrent malignant disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent cytotoxic drug experimental therapy ( e.g. , antiangiogenic drug , tyrosine kinase inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>